Novogen, Yale To Create JV To Develop Ovarian Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Australia's Novogen and Yale University of the U.S. plan to set up a joint venture to develop personalized treatments for ovarian cancer under the name of CanTx.